1. Man, Jing, Zhou, Wanbiao, Zuo, Shi, Ma, Huaxing, Li, Hai-Yang. 2023. TANGO1 interacts with NRTN to promote hepatocellular carcinoma progression by regulating the PI3K/AKT/mTOR signaling pathway. In Biochemical pharmacology, 213, 115615. doi:10.1016/j.bcp.2023.115615. https://pubmed.ncbi.nlm.nih.gov/37211171/
2. Axelsen, Tobias M, Woldbye, David P D. . Gene Therapy for Parkinson's Disease, An Update. In Journal of Parkinson's disease, 8, 195-215. doi:10.3233/JPD-181331. https://pubmed.ncbi.nlm.nih.gov/29710735/
3. Butler Tjaden, Naomi E, Trainor, Paul A. 2013. The developmental etiology and pathogenesis of Hirschsprung disease. In Translational research : the journal of laboratory and clinical medicine, 162, 1-15. doi:10.1016/j.trsl.2013.03.001. https://pubmed.ncbi.nlm.nih.gov/23528997/
4. Wright, Christina M, Schneider, Sabine, Smith-Edwards, Kristen M, Davis, Brian M, Heuckeroth, Robert O. 2021. scRNA-Seq Reveals New Enteric Nervous System Roles for GDNF, NRTN, and TBX3. In Cellular and molecular gastroenterology and hepatology, 11, 1548-1592.e1. doi:10.1016/j.jcmgh.2020.12.014. https://pubmed.ncbi.nlm.nih.gov/33444816/
5. Correia, Jorge C, Kelahmetoglu, Yildiz, Jannig, Paulo R, Hedlund, Eva, Ruas, Jorge L. 2021. Muscle-secreted neurturin couples myofiber oxidative metabolism and slow motor neuron identity. In Cell metabolism, 33, 2215-2230.e8. doi:10.1016/j.cmet.2021.09.003. https://pubmed.ncbi.nlm.nih.gov/34592133/
6. Li, Liqun, Yan, Jing, Liu, Qian, Liu, Lijian, Xie, Sheng. . Association of MCP-4, NRTN, and PD-L1 with the risk of hepatic fibrosis: A Mendelian randomization study. In Medicine, 103, e39655. doi:10.1097/MD.0000000000039655. https://pubmed.ncbi.nlm.nih.gov/39252214/
7. Sato, Suguru, Suzuki, Yasuhito, Kikuchi, Masami, Saito, Junpei, Shibata, Yoko. 2023. Sputum Neurturin Levels in Adult Asthmatic Subjects. In Journal of asthma and allergy, 16, 889-901. doi:10.2147/JAA.S421742. https://pubmed.ncbi.nlm.nih.gov/37671183/
8. Bartus, Raymond T, Brown, Lamar, Wilson, Alistair, Kordower, Jeffrey H, Herzog, Christopher D. 2011. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. In Neurobiology of disease, 44, 38-52. doi:10.1016/j.nbd.2011.05.026. https://pubmed.ncbi.nlm.nih.gov/21704161/
9. Wang, Shuyun, Nie, Limin, Song, Yuxiao, Dang, Qi, Gao, Aiqin. 2022. Neurturin promotes tumor cell motility and angiogenesis in colorectal cancer. In Experimental cell research, 413, 113049. doi:10.1016/j.yexcr.2022.113049. https://pubmed.ncbi.nlm.nih.gov/35114191/
10. Marks, William J, Baumann, Tiffany L, Bartus, Raymond T. 2016. Long-Term Safety of Patients with Parkinson's Disease Receiving rAAV2-Neurturin (CERE-120) Gene Transfer. In Human gene therapy, 27, 522-7. doi:10.1089/hum.2015.134. https://pubmed.ncbi.nlm.nih.gov/26711317/